Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 1/20 | 0.41 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL862131 | 0.91 | PPARG (0.47) | CYP2C8PPARGMAPTTP53AKR1C3 | |
| SCHEMBL831437 | 0.89 | CYP2C8 (0.41) | CYP2C8PPARGMAPTKMT2ALMNA | |
| SCHEMBL862472 | 0.87 | CYP2C8 (0.43) | CYP2C8PPARGMAPTKMT2AMEN1 | |
| SCHEMBL862266 | 0.87 | CYP2C8 (0.48) | CYP2C8PPARGMAPTAKR1C3AKR1C2 | |
| SCHEMBL862217 | 0.86 | PPARG (0.43) | CYP2C8PPARGMAPTTP53PTGS2 | |
| SCHEMBL862166 | 0.85 | CYP2C8 (0.42) | CYP2C8PPARGAKR1C3AKR1C2KMT2A | |
| SCHEMBL862560 | 0.85 | FLT1 (0.42) | CYP2C8PPARGAKR1C3AKR1C2KMT2A | |
| SCHEMBL831268 | 0.85 | CYP2C8 (0.45) | CYP2C8PPARGMAPTKMT2AMEN1 | |
| SCHEMBL862164 | 0.85 | CYP2C8 (0.42) | CYP2C8PPARGMAPTKMT2AMEN1 | |
| SCHEMBL862473 | 0.85 | CYP2C8 (0.43) | CYP2C8MAPTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143305-B2 | 2,3-substituted indole derivatives for treating viral infections | SCHERING CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | IDO2, IDO1, IRF3 | ALPL 4279/4885CYP2C8 847/4885PPARG 4093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.